NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Medivir AB (publ) (ST: MVIR-B)

 
MVIR-B Technical Analysis
5
As on 17th Jul 2023 MVIR-B STOCK Price closed @ 7.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 8.12 & Strong Sell for SHORT-TERM with Stoploss of 8.16 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MVIR-BSTOCK Price

Open 6.83 Change Price %
High 7.39 1 Day -0.09 -1.27
Low 6.83 1 Week 0.05 0.72
Close 7.00 1 Month -0.65 -8.50
Volume 6245 1 Year -1.58 -18.41
52 Week High 10.02 | 52 Week Low 6.91
 
ST Sweden Most Active Stocks
FING-B 0.03 -25.00%
WYLD 0.01 0.00%
SBB-B 4.10 0.49%
TELIA 30.18 -0.26%
HDW-B 0.00 %
CYB1 0.01 0.00%
NIBE-B 42.17 0.19%
LUNE 21.97 6.65%
ERIC-B 89.10 -0.13%
ABLI 0.42 0.00%
 
ST Sweden Top Gainers Stocks
KOPY 0.10 150.00%
DIABIO 0.03 50.00%
AVT-B 5.68 43.80%
SPIFF 0.04 33.33%
SEDANA 18.96 23.44%
IBT-B 59.00 18.00%
NILS 3.48 15.23%
FEEL 0.09 12.50%
IS 2.60 12.07%
IS 2.60 12.07%
 
ST Sweden Top Losers Stocks
XMR 0.01 -50.00%
SIMRIS-B 0.05 -28.57%
ALLR 1.55 -26.54%
FING-B 0.03 -25.00%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
SPEC 2.75 -18.40%
SPEC 2.75 -18.40%
SPEC 2.75 -18.40%
 
 
MVIR-B
Daily Charts
MVIR-B
Intraday Charts
Whats New @
Bazaartrend
MVIR-B
Free Analysis
 
MVIR-B Important Levels Intraday
RESISTANCE8.08
RESISTANCE7.73
RESISTANCE7.52
RESISTANCE7.31
SUPPORT6.69
SUPPORT6.48
SUPPORT6.27
SUPPORT5.92
 
MVIR-B Forecast December 2024
4th UP Forecast10.06
3rd UP Forecast9.08
2nd UP Forecast8.47
1st UP Forecast7.87
1st DOWN Forecast6.13
2nd DOWN Forecast5.53
3rd DOWN Forecast4.92
4th DOWN Forecast3.94
 
MVIR-B Weekly Forecast
4th UP Forecast8.43
3rd UP Forecast7.97
2nd UP Forecast7.69
1st UP Forecast7.40
1st DOWN Forecast6.60
2nd DOWN Forecast6.31
3rd DOWN Forecast6.03
4th DOWN Forecast5.57
 
MVIR-B Forecast2024
4th UP Forecast14.15
3rd UP Forecast11.86
2nd UP Forecast10.44
1st UP Forecast9.02
1st DOWN Forecast4.98
2nd DOWN Forecast3.56
3rd DOWN Forecast2.14
4th DOWN Forecast-0.15
 
 
MVIR-B Other Details
Segment EQ
Market Capital 533393504.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MVIR-B Address
MVIR-B
 
MVIR-B Latest News
 
Your Comments and Response on Medivir AB (publ)
 
MVIR-B Business Profile
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name; and simeprevir. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; and MIV-711, which is in phase II clinical trial for treating osteoarthritis. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden. Address: Lunastigen 7, Huddinge, Sweden, 141 22
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service